CBD
Congress Picks Up the Baton from the FDA on CBD, Seeking Data
The unregulated hemp-derived cannabinoid marketplace has exploded since the 2018 Farm Bill descheduled hemp. The FDA has asked Congress to help with a “new regulatory pathway.”
FDA’s Cannabis Advisor: Approach to CBD Rules Shouldn’t Let “Perfect be the Enemy of the Good”
Norman Birenbaum spoke about the FDA’s cannabis-related efforts during a discussion on Thursday hosted by the Council for Federal Cannabis Regulation.
As the FDA Turns to Congress for CBD Regs, Here’s Who’s Been Lobbying on CBD
Now that Congress will play a bigger role in the future of the CBD industry, will more companies try to sway the outcome?
FDA Announces Plan to Work with Congress on “New” Path for CBD Products
The cannabis industry has long-awaited rules from the FDA to guide the CBD industry. Now, it’s up to Congress.
FDA Issues More CBD Warning Letters, With a Focus on Covid Claims
The 2018 Farm Bill legalized hemp, and, by extension, hemp-derived CBD, but the Food and Drug Administration has not yet released rules to guide the growing industry.
FDA Reiterates Need for Cannabinoid Data in Webinar on Research and Regulation
The Food and Drug Administration has said for years that it is working on rules for cannabinoid-containing products. But it has also said that crucial research and data are lacking.
FDA: The Cannabis Regulatory Landscape is “Complex”
A policy coordinator with the FDA’s Cannabis Product Committee spoke about CBD during a Food and Drug Law Institute event focused on cannabis.
FDA Launches Biggest Cannabis Data Collection Plan Yet
The Food and Drug Administration has been on a march to collect cannabinoid-related data. The “Cannabis-Derived Products Data Acceleration Plan” released this month is its most robust effort.
FDA Rejects Two Applications for CBD-based Dietary Supplements
Epidiolex strikes again: the FDA-approved CBD-based pharmaceutical is complicating other uses of CBD.
Cannabis and Clinical Trials: How the First Cannabis Extract Got FDA Approval
CSU Pueblo hosted a pharmacist at Greenwich Biosciences to talk about the company’s path with Epidiolex, a CBD-based medicine extracted from cannabis plants.
Consumer Brands Association Pushes Lawmakers on CBD Amid FDA Inaction
The group, which includes Coca-Cola and Kellogg’s as members, says its membership is “CBD curious” but that the lack of federal regulation is keeping major brands at bay.
Hemp in Animal Food: Is a Path Taking Shape?
“I’m getting very hopeful that we're headed down the road to seeing some hemp-derived ingredients approved for use in animal food,” said the FDA’s Deputy Director in the Division of Animal Feeds.
Amid Pressure to Publish CBD Rules, FDA Reiterates Need for “Better Data”
The FDA, which has been crafting rules for CBD products since 2019, says it is seeking partnerships, from academia to government and the cannabis industry, to “develop the foundation for more robust CBD data collection.”
FDA, DOJ Officials Talk Cannabis and CBD at Food and Drug Conference
The Food and Drug Law Institute is hosting officials from several federal agencies this week to discuss cannabis policies.
GW Pharmaceuticals and GNC met with White House on CBD
One company is focused on the future of CBD in supplements. The other, on its future in pharmaceuticals.
The FDA Wants to Help Cannabis Businesses Advance Research
During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.
